Biological innovation · Umeå, Sweden

A clearer path through enzyme innovation.

Vakona is developing a novel enzyme-based approach with the potential to transform how acne-prone skin is addressed. By harnessing the precision of a naturally derived enzyme, our technology creates new possibilities for science-led skincare and future therapeutic applications.

Explore the science Discover Vakona

Microscopic view representing Vakona’s biological research

Research focusBiofilm-degrading enzyme

Natural active substance

TargetC. acnes biofilm

~240 millionpeople worldwide are living with acne

10+ yearsof acne research behind the technology

01 / About Vakona

Treat the biofilm.
Not the bacterium.

Most acne products target the bacterium. Vakona targets the protective structure around it.

An imbalance in the skin microbiome plays a central role in acne. By forming biofilms, Cutibacterium acnes can promote inflammation and shield itself from the body’s immune defenses and conventional treatments.

Vakona’s planned topical product is based on a naturally occurring bacterial enzyme that degrades this biofilm. The technology has the potential to significantly shorten treatment time—without the skin irritation and antibiotic resistance associated with many existing therapies.

Comparison of bacterial growth and biofilm — A different therapeutic target can unlock a different treatment outcome.

02 / The condition

One of the world’s most common skin conditions deserves a better standard of care.

Acne vulgaris affects more than 80% of adolescents and young adults—and its impact reaches far beyond the skin.

It can deeply affect self-esteem, social confidence and mental health, with consequences that may persist long after active acne has cleared.

Current acne products and treatments can be irritating, slow to deliver results and difficult to sustain, while antibiotic-based therapies face the growing challenge of resistance.

Why now

The need for effective, well-tolerated acne solutions is growing, while antibiotic resistance is increasing the pressure to find new approaches.

Microscope image of P. acnes biofilm — Biofilm formationBacteria embedded in a protective matrix can contribute to therapeutic failure.

The scale

A global challenge. A focused approach.

Acne is a widespread condition with needs spanning both medical treatment and consumer skincare. Vakona’s technology has the potential to address this challenge across multiple applications.

Global acne drugs market, 2026$10.7B

Global anti-acne cosmetics market, 2026$6.2B

03 / Technology

A natural enzyme.
A novel mechanism.

Built on Dr. Oleg Alexeyev’s decade-long acne research, Vakona’s topical technology uses a naturally derived bacterial enzyme as its key active ingredient.

The enzyme is being developed for use on the skin, where it is designed to act directly on the biofilm associated with acne-prone skin.